Phase I trial of daily triapine in combination with cisplatin chemotherapy for advanced-stage malignancies View Full Text


Ontology type: schema:ScholarlyArticle      Open Access: True


Article Info

DATE

2016-11-22

AUTHORS

Charles A. Kunos, Edward Chu, Jan H. Beumer, Mario Sznol, S. Percy Ivy

ABSTRACT

PurposeAdvanced-stage malignancies have increased deoxyribonucleotide demands in DNA replication and repair, making deoxyribonucleotide supply a potential exploitable target for therapy based on ribonucleotide reductase (RNR) inhibition.MethodsA dose-finding phase I trial was conducted of intravenous (i.v.) triapine, a small-molecule RNR inhibitor, and cisplatin chemotherapy in patients with advanced-stage solid tumor malignancies. Patients received dose-finding levels of i.v. triapine (48–96 mg/m2) and i.v. cisplatin (20–75 mg/m2) on 1 of 3 different schedules. The primary endpoint was to identify the maximum tolerated dose of a triapine–cisplatin combination. Secondary endpoints included the rate of triapine–cisplatin objective response and the pharmacokinetics and bioavailability of a single oral triapine dose. (Clinicaltrials.gov number, NCT00024323).ResultsThe MTD was 96 mg/m2 triapine daily days 1–4 and 75 mg/m2 cisplatin split over day 2 and day 3. Frequent grade 3 or 4 adverse events included fatigue, dyspnea, leukopenia, thrombocytopenia, and electrolyte abnormalities. No objective responses were observed; 5 (50%) of 10 patients treated at the MTD had stable disease. Pharmacokinetics indicated an oral triapine bioavailability of 88%.ConclusionsThe triapine–cisplatin combination may be given safely in patients with advanced-stage solid tumor malignancies. On the basis of these results, a phase I trial adequately powered to evaluate oral triapine bioavailability in women with advanced-stage uterine cervix or vulvar cancers is underway. More... »

PAGES

201-207

Identifiers

URI

http://scigraph.springernature.com/pub.10.1007/s00280-016-3200-x

DOI

http://dx.doi.org/10.1007/s00280-016-3200-x

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1031872608

PUBMED

https://www.ncbi.nlm.nih.gov/pubmed/27878356


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1112", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Oncology and Carcinogenesis", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Adult", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Aged", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Aged, 80 and over", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Antineoplastic Combined Chemotherapy Protocols", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Cisplatin", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Female", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Humans", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Infusions, Intravenous", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Male", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Middle Aged", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Neoplasm Staging", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Neoplasms", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Pyridines", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Ribonucleotide Reductases", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Thiosemicarbazones", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "alternateName": "Investigational Drug Branch, Cancer Therapy Evaluation Program, Division of Cancer Treatment and Diagnosis, National Cancer Institute, National Institutes of Health, 9609 Medical Center Drive, MSC 9739, 20892-9760, Rockville, MD, USA", 
          "id": "http://www.grid.ac/institutes/grid.48336.3a", 
          "name": [
            "Cancer Therapy Evaluation Program, National Cancer Institute, Bethesda, MD, USA", 
            "Investigational Drug Branch, Cancer Therapy Evaluation Program, Division of Cancer Treatment and Diagnosis, National Cancer Institute, National Institutes of Health, 9609 Medical Center Drive, MSC 9739, 20892-9760, Rockville, MD, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Kunos", 
        "givenName": "Charles A.", 
        "id": "sg:person.01315043163.01", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01315043163.01"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "University of Pittsburgh School of Medicine, Pittsburgh, PA, USA", 
          "id": "http://www.grid.ac/institutes/grid.21925.3d", 
          "name": [
            "University of Pittsburgh School of Medicine, Pittsburgh, PA, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Chu", 
        "givenName": "Edward", 
        "id": "sg:person.01003652000.28", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01003652000.28"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "University of Pittsburgh School of Pharmacy, Pittsburgh, PA, USA", 
          "id": "http://www.grid.ac/institutes/grid.21925.3d", 
          "name": [
            "University of Pittsburgh School of Medicine, Pittsburgh, PA, USA", 
            "Cancer Therapeutics Program, University of Pittsburgh Cancer Institute, Pittsburgh, PA, USA", 
            "University of Pittsburgh School of Pharmacy, Pittsburgh, PA, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Beumer", 
        "givenName": "Jan H.", 
        "id": "sg:person.01154766121.36", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01154766121.36"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Yale University School of Medicine and Yale Cancer Center, New Haven, CT, USA", 
          "id": "http://www.grid.ac/institutes/grid.47100.32", 
          "name": [
            "Yale University School of Medicine and Yale Cancer Center, New Haven, CT, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Sznol", 
        "givenName": "Mario", 
        "id": "sg:person.0706626451.72", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0706626451.72"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Cancer Therapy Evaluation Program, National Cancer Institute, Bethesda, MD, USA", 
          "id": "http://www.grid.ac/institutes/grid.48336.3a", 
          "name": [
            "Cancer Therapy Evaluation Program, National Cancer Institute, Bethesda, MD, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Ivy", 
        "givenName": "S. Percy", 
        "id": "sg:person.01234474774.39", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01234474774.39"
        ], 
        "type": "Person"
      }
    ], 
    "citation": [
      {
        "id": "sg:pub.10.1038/nsmb.2007", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1041944342", 
          "https://doi.org/10.1038/nsmb.2007"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1186/1479-5876-10-79", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1046418577", 
          "https://doi.org/10.1186/1479-5876-10-79"
        ], 
        "type": "CreativeWork"
      }
    ], 
    "datePublished": "2016-11-22", 
    "datePublishedReg": "2016-11-22", 
    "description": "PurposeAdvanced-stage malignancies have increased deoxyribonucleotide demands in DNA replication and repair, making deoxyribonucleotide supply a potential exploitable target for therapy based on ribonucleotide reductase (RNR) inhibition.MethodsA dose-finding phase I trial was conducted of intravenous (i.v.) triapine, a small-molecule RNR inhibitor, and cisplatin chemotherapy in patients with advanced-stage solid tumor malignancies. Patients received dose-finding levels of i.v. triapine (48\u201396\u00a0mg/m2) and i.v. cisplatin (20\u201375\u00a0mg/m2) on 1 of 3 different schedules. The primary endpoint was to identify the maximum tolerated dose of a triapine\u2013cisplatin combination. Secondary endpoints included the rate of triapine\u2013cisplatin objective response and the pharmacokinetics and bioavailability of a single oral triapine dose. (Clinicaltrials.gov number, NCT00024323).ResultsThe MTD was 96\u00a0mg/m2 triapine daily days 1\u20134 and 75\u00a0mg/m2 cisplatin split over day 2 and day 3. Frequent grade 3 or 4 adverse events included fatigue, dyspnea, leukopenia, thrombocytopenia, and electrolyte abnormalities. No objective responses were observed; 5 (50%) of 10 patients treated at the MTD had stable disease. Pharmacokinetics indicated an oral triapine bioavailability of 88%.ConclusionsThe triapine\u2013cisplatin combination may be given safely in patients with advanced-stage solid tumor malignancies. On the basis of these results, a phase I trial adequately powered to evaluate oral triapine bioavailability in women with advanced-stage uterine cervix or vulvar cancers is underway.", 
    "genre": "article", 
    "id": "sg:pub.10.1007/s00280-016-3200-x", 
    "isAccessibleForFree": true, 
    "isFundedItemOf": [
      {
        "id": "sg:grant.3536166", 
        "type": "MonetaryGrant"
      }, 
      {
        "id": "sg:grant.2438856", 
        "type": "MonetaryGrant"
      }
    ], 
    "isPartOf": [
      {
        "id": "sg:journal.1088364", 
        "issn": [
          "0344-5704", 
          "1432-0843"
        ], 
        "name": "Cancer Chemotherapy and Pharmacology", 
        "publisher": "Springer Nature", 
        "type": "Periodical"
      }, 
      {
        "issueNumber": "1", 
        "type": "PublicationIssue"
      }, 
      {
        "type": "PublicationVolume", 
        "volumeNumber": "79"
      }
    ], 
    "keywords": [
      "phase I trial", 
      "solid tumor malignancies", 
      "I trial", 
      "objective response", 
      "tumor malignancy", 
      "daily days 1", 
      "frequent grade 3", 
      "advanced-stage malignancies", 
      "dose-finding phase I trial", 
      "ResultsThe MTD", 
      "stable disease", 
      "primary endpoint", 
      "secondary endpoints", 
      "vulvar cancer", 
      "electrolyte abnormalities", 
      "adverse events", 
      "uterine cervix", 
      "cisplatin chemotherapy", 
      "grade 3", 
      "day 1", 
      "day 2", 
      "day 3", 
      "patients", 
      "malignancy", 
      "different schedules", 
      "reductase inhibition", 
      "trials", 
      "chemotherapy", 
      "pharmacokinetics", 
      "MTD", 
      "exploitable target", 
      "cisplatin", 
      "dose", 
      "endpoint", 
      "ribonucleotide reductase inhibition", 
      "bioavailability", 
      "Triapine", 
      "dyspnea", 
      "leukopenia", 
      "thrombocytopenia", 
      "cervix", 
      "therapy", 
      "cancer", 
      "abnormalities", 
      "disease", 
      "response", 
      "women", 
      "RNR inhibitors", 
      "inhibitors", 
      "inhibition", 
      "repair", 
      "combination", 
      "fatigue", 
      "target", 
      "levels", 
      "schedule", 
      "replication", 
      "rate", 
      "events", 
      "DNA replication", 
      "results", 
      "basis", 
      "supply", 
      "maximum", 
      "demand"
    ], 
    "name": "Phase I trial of daily triapine in combination with cisplatin chemotherapy for advanced-stage malignancies", 
    "pagination": "201-207", 
    "productId": [
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1031872608"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1007/s00280-016-3200-x"
        ]
      }, 
      {
        "name": "pubmed_id", 
        "type": "PropertyValue", 
        "value": [
          "27878356"
        ]
      }
    ], 
    "sameAs": [
      "https://doi.org/10.1007/s00280-016-3200-x", 
      "https://app.dimensions.ai/details/publication/pub.1031872608"
    ], 
    "sdDataset": "articles", 
    "sdDatePublished": "2022-11-24T21:01", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-springernature-scigraph/baseset/20221124/entities/gbq_results/article/article_711.jsonl", 
    "type": "ScholarlyArticle", 
    "url": "https://doi.org/10.1007/s00280-016-3200-x"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1007/s00280-016-3200-x'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1007/s00280-016-3200-x'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1007/s00280-016-3200-x'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1007/s00280-016-3200-x'


 

This table displays all metadata directly associated to this object as RDF triples.

237 TRIPLES      21 PREDICATES      107 URIs      97 LITERALS      22 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1007/s00280-016-3200-x schema:about N0a379e995d164c69b39cfe4776e46366
2 N259816fd94e2407ab9bf6beefad6ac27
3 N3c96fd1bc2f9453bbd76a08e808dbafb
4 N4db79bc6a13e44dc9e3dfbb4d23828e0
5 N527a6cb9e2f743b897f5b5c085f2c610
6 N6ca0131b071a4399b62d9b474846b23b
7 N7fff822b0af54c109cbebd640d11aa5e
8 Naa1310e5f69f418ba3ecf3331696cda7
9 Naafe30fb3f244aa78f57b95d7c7811bd
10 Nbe3971c4f3934f65a6508d95b378e287
11 Nbfe3a39392a34615a0c85cee6a1c97d0
12 Nc33358882203464c8625f20622fbf326
13 Ncfb91cac2b9f4e37ac1614877cd933a1
14 Nd6209bb8c06d41e4befb9507c98772dd
15 Nd90e91c4eb124d838b5064e8f0c27d36
16 anzsrc-for:11
17 anzsrc-for:1112
18 schema:author Nd0e60bf8f4a14ec089b4834d73c352ad
19 schema:citation sg:pub.10.1038/nsmb.2007
20 sg:pub.10.1186/1479-5876-10-79
21 schema:datePublished 2016-11-22
22 schema:datePublishedReg 2016-11-22
23 schema:description PurposeAdvanced-stage malignancies have increased deoxyribonucleotide demands in DNA replication and repair, making deoxyribonucleotide supply a potential exploitable target for therapy based on ribonucleotide reductase (RNR) inhibition.MethodsA dose-finding phase I trial was conducted of intravenous (i.v.) triapine, a small-molecule RNR inhibitor, and cisplatin chemotherapy in patients with advanced-stage solid tumor malignancies. Patients received dose-finding levels of i.v. triapine (48–96 mg/m2) and i.v. cisplatin (20–75 mg/m2) on 1 of 3 different schedules. The primary endpoint was to identify the maximum tolerated dose of a triapine–cisplatin combination. Secondary endpoints included the rate of triapine–cisplatin objective response and the pharmacokinetics and bioavailability of a single oral triapine dose. (Clinicaltrials.gov number, NCT00024323).ResultsThe MTD was 96 mg/m2 triapine daily days 1–4 and 75 mg/m2 cisplatin split over day 2 and day 3. Frequent grade 3 or 4 adverse events included fatigue, dyspnea, leukopenia, thrombocytopenia, and electrolyte abnormalities. No objective responses were observed; 5 (50%) of 10 patients treated at the MTD had stable disease. Pharmacokinetics indicated an oral triapine bioavailability of 88%.ConclusionsThe triapine–cisplatin combination may be given safely in patients with advanced-stage solid tumor malignancies. On the basis of these results, a phase I trial adequately powered to evaluate oral triapine bioavailability in women with advanced-stage uterine cervix or vulvar cancers is underway.
24 schema:genre article
25 schema:isAccessibleForFree true
26 schema:isPartOf N13c55d404ea64da98864f3b1859dc8ea
27 Ncec004cda57f4d6dba1d22fe5c2dfce0
28 sg:journal.1088364
29 schema:keywords DNA replication
30 I trial
31 MTD
32 RNR inhibitors
33 ResultsThe MTD
34 Triapine
35 abnormalities
36 advanced-stage malignancies
37 adverse events
38 basis
39 bioavailability
40 cancer
41 cervix
42 chemotherapy
43 cisplatin
44 cisplatin chemotherapy
45 combination
46 daily days 1
47 day 1
48 day 2
49 day 3
50 demand
51 different schedules
52 disease
53 dose
54 dose-finding phase I trial
55 dyspnea
56 electrolyte abnormalities
57 endpoint
58 events
59 exploitable target
60 fatigue
61 frequent grade 3
62 grade 3
63 inhibition
64 inhibitors
65 leukopenia
66 levels
67 malignancy
68 maximum
69 objective response
70 patients
71 pharmacokinetics
72 phase I trial
73 primary endpoint
74 rate
75 reductase inhibition
76 repair
77 replication
78 response
79 results
80 ribonucleotide reductase inhibition
81 schedule
82 secondary endpoints
83 solid tumor malignancies
84 stable disease
85 supply
86 target
87 therapy
88 thrombocytopenia
89 trials
90 tumor malignancy
91 uterine cervix
92 vulvar cancer
93 women
94 schema:name Phase I trial of daily triapine in combination with cisplatin chemotherapy for advanced-stage malignancies
95 schema:pagination 201-207
96 schema:productId N5071b070fcbf49cfb6febb01e14ec464
97 Nb4490a6f0b004bc0a1fc26a784c03267
98 Nfe5c3b7bf5894ae69cdead37d8754b20
99 schema:sameAs https://app.dimensions.ai/details/publication/pub.1031872608
100 https://doi.org/10.1007/s00280-016-3200-x
101 schema:sdDatePublished 2022-11-24T21:01
102 schema:sdLicense https://scigraph.springernature.com/explorer/license/
103 schema:sdPublisher Ncf660c51a6394b768afecc8dbe28011f
104 schema:url https://doi.org/10.1007/s00280-016-3200-x
105 sgo:license sg:explorer/license/
106 sgo:sdDataset articles
107 rdf:type schema:ScholarlyArticle
108 N0a379e995d164c69b39cfe4776e46366 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
109 schema:name Ribonucleotide Reductases
110 rdf:type schema:DefinedTerm
111 N0ce80ad10eb240e19ad59f2a48a53363 rdf:first sg:person.01234474774.39
112 rdf:rest rdf:nil
113 N13c55d404ea64da98864f3b1859dc8ea schema:issueNumber 1
114 rdf:type schema:PublicationIssue
115 N259816fd94e2407ab9bf6beefad6ac27 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
116 schema:name Humans
117 rdf:type schema:DefinedTerm
118 N3c96fd1bc2f9453bbd76a08e808dbafb schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
119 schema:name Antineoplastic Combined Chemotherapy Protocols
120 rdf:type schema:DefinedTerm
121 N48869faf026248379d75e195f9d15d15 rdf:first sg:person.01003652000.28
122 rdf:rest N493ec90406d540c68d4e8d41062172a6
123 N493ec90406d540c68d4e8d41062172a6 rdf:first sg:person.01154766121.36
124 rdf:rest Na9752ce930cc49feb74f1ac5b645f85a
125 N4db79bc6a13e44dc9e3dfbb4d23828e0 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
126 schema:name Middle Aged
127 rdf:type schema:DefinedTerm
128 N5071b070fcbf49cfb6febb01e14ec464 schema:name doi
129 schema:value 10.1007/s00280-016-3200-x
130 rdf:type schema:PropertyValue
131 N527a6cb9e2f743b897f5b5c085f2c610 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
132 schema:name Cisplatin
133 rdf:type schema:DefinedTerm
134 N6ca0131b071a4399b62d9b474846b23b schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
135 schema:name Female
136 rdf:type schema:DefinedTerm
137 N7fff822b0af54c109cbebd640d11aa5e schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
138 schema:name Pyridines
139 rdf:type schema:DefinedTerm
140 Na9752ce930cc49feb74f1ac5b645f85a rdf:first sg:person.0706626451.72
141 rdf:rest N0ce80ad10eb240e19ad59f2a48a53363
142 Naa1310e5f69f418ba3ecf3331696cda7 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
143 schema:name Infusions, Intravenous
144 rdf:type schema:DefinedTerm
145 Naafe30fb3f244aa78f57b95d7c7811bd schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
146 schema:name Thiosemicarbazones
147 rdf:type schema:DefinedTerm
148 Nb4490a6f0b004bc0a1fc26a784c03267 schema:name dimensions_id
149 schema:value pub.1031872608
150 rdf:type schema:PropertyValue
151 Nbe3971c4f3934f65a6508d95b378e287 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
152 schema:name Aged
153 rdf:type schema:DefinedTerm
154 Nbfe3a39392a34615a0c85cee6a1c97d0 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
155 schema:name Aged, 80 and over
156 rdf:type schema:DefinedTerm
157 Nc33358882203464c8625f20622fbf326 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
158 schema:name Adult
159 rdf:type schema:DefinedTerm
160 Ncec004cda57f4d6dba1d22fe5c2dfce0 schema:volumeNumber 79
161 rdf:type schema:PublicationVolume
162 Ncf660c51a6394b768afecc8dbe28011f schema:name Springer Nature - SN SciGraph project
163 rdf:type schema:Organization
164 Ncfb91cac2b9f4e37ac1614877cd933a1 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
165 schema:name Neoplasms
166 rdf:type schema:DefinedTerm
167 Nd0e60bf8f4a14ec089b4834d73c352ad rdf:first sg:person.01315043163.01
168 rdf:rest N48869faf026248379d75e195f9d15d15
169 Nd6209bb8c06d41e4befb9507c98772dd schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
170 schema:name Male
171 rdf:type schema:DefinedTerm
172 Nd90e91c4eb124d838b5064e8f0c27d36 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
173 schema:name Neoplasm Staging
174 rdf:type schema:DefinedTerm
175 Nfe5c3b7bf5894ae69cdead37d8754b20 schema:name pubmed_id
176 schema:value 27878356
177 rdf:type schema:PropertyValue
178 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
179 schema:name Medical and Health Sciences
180 rdf:type schema:DefinedTerm
181 anzsrc-for:1112 schema:inDefinedTermSet anzsrc-for:
182 schema:name Oncology and Carcinogenesis
183 rdf:type schema:DefinedTerm
184 sg:grant.2438856 http://pending.schema.org/fundedItem sg:pub.10.1007/s00280-016-3200-x
185 rdf:type schema:MonetaryGrant
186 sg:grant.3536166 http://pending.schema.org/fundedItem sg:pub.10.1007/s00280-016-3200-x
187 rdf:type schema:MonetaryGrant
188 sg:journal.1088364 schema:issn 0344-5704
189 1432-0843
190 schema:name Cancer Chemotherapy and Pharmacology
191 schema:publisher Springer Nature
192 rdf:type schema:Periodical
193 sg:person.01003652000.28 schema:affiliation grid-institutes:grid.21925.3d
194 schema:familyName Chu
195 schema:givenName Edward
196 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01003652000.28
197 rdf:type schema:Person
198 sg:person.01154766121.36 schema:affiliation grid-institutes:grid.21925.3d
199 schema:familyName Beumer
200 schema:givenName Jan H.
201 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01154766121.36
202 rdf:type schema:Person
203 sg:person.01234474774.39 schema:affiliation grid-institutes:grid.48336.3a
204 schema:familyName Ivy
205 schema:givenName S. Percy
206 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01234474774.39
207 rdf:type schema:Person
208 sg:person.01315043163.01 schema:affiliation grid-institutes:grid.48336.3a
209 schema:familyName Kunos
210 schema:givenName Charles A.
211 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01315043163.01
212 rdf:type schema:Person
213 sg:person.0706626451.72 schema:affiliation grid-institutes:grid.47100.32
214 schema:familyName Sznol
215 schema:givenName Mario
216 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0706626451.72
217 rdf:type schema:Person
218 sg:pub.10.1038/nsmb.2007 schema:sameAs https://app.dimensions.ai/details/publication/pub.1041944342
219 https://doi.org/10.1038/nsmb.2007
220 rdf:type schema:CreativeWork
221 sg:pub.10.1186/1479-5876-10-79 schema:sameAs https://app.dimensions.ai/details/publication/pub.1046418577
222 https://doi.org/10.1186/1479-5876-10-79
223 rdf:type schema:CreativeWork
224 grid-institutes:grid.21925.3d schema:alternateName University of Pittsburgh School of Medicine, Pittsburgh, PA, USA
225 University of Pittsburgh School of Pharmacy, Pittsburgh, PA, USA
226 schema:name Cancer Therapeutics Program, University of Pittsburgh Cancer Institute, Pittsburgh, PA, USA
227 University of Pittsburgh School of Medicine, Pittsburgh, PA, USA
228 University of Pittsburgh School of Pharmacy, Pittsburgh, PA, USA
229 rdf:type schema:Organization
230 grid-institutes:grid.47100.32 schema:alternateName Yale University School of Medicine and Yale Cancer Center, New Haven, CT, USA
231 schema:name Yale University School of Medicine and Yale Cancer Center, New Haven, CT, USA
232 rdf:type schema:Organization
233 grid-institutes:grid.48336.3a schema:alternateName Cancer Therapy Evaluation Program, National Cancer Institute, Bethesda, MD, USA
234 Investigational Drug Branch, Cancer Therapy Evaluation Program, Division of Cancer Treatment and Diagnosis, National Cancer Institute, National Institutes of Health, 9609 Medical Center Drive, MSC 9739, 20892-9760, Rockville, MD, USA
235 schema:name Cancer Therapy Evaluation Program, National Cancer Institute, Bethesda, MD, USA
236 Investigational Drug Branch, Cancer Therapy Evaluation Program, Division of Cancer Treatment and Diagnosis, National Cancer Institute, National Institutes of Health, 9609 Medical Center Drive, MSC 9739, 20892-9760, Rockville, MD, USA
237 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...